Nabi Biopharmaceuticals, which this week disclosed a lead product failed in a late-stage trial, has canceled its lease for a 102,000-square-foot research and development facility in Gaithersburg, Md. The Boca Raton-based biotech would have grown in that city. Nabi (NASDAQ: NABI - News) already employs about 165 people in Rockville, Md., where it uses several older buildings. The firm is assessing its next move after reporting a Phase III study of its vaccine to prevent staph infections in patients with serious kidney problems did not meet its objective. The disclosure sent shares of Nabi down about 70 percent in trading Tuesday. Many analysts, industry observers and health care providers had been confident the product, called StaphVAX, would be a success this time around after not meeting its objective in a first Phase III trial several years ago. A Nabi spokeswoman said the company has not made any decisions whether to cut jobs or relocate workers from Rockville to Boca Raton. Nabi had the right to expand in Gaithersburg by up to 120,000 square feet. The lease began June 30 and was for an initial term of 12 and a half years, ending Dec. 31, 2017. Rent would begin Jan. 1, 2006, at $2.31 million a year and included $5.14 million in tenant improvements to be paid by the owner and included in the base rent. In the lease agreement was an option to terminate but written notice from Nabi needed to be sent to the landlord by Nov. 1, accompanied by $771,000 as a termination fee. Nabi must also reimburse the landlord for the amount of the tenant improvement allowance within 30 days. As a result of this week’s failed Phase III study, Nabi is to halt development work on StaphVAX and a related product as its examines Phase III data.